Report cover image

U.S. Artificial Intelligence in Manufacturing Market Size, Share, Trends, Industry Analysis Report By Component (Hardware, Software), By Technology, By Application, By End Use – Market Forecast, 2025–2034

Published Sep 01, 2025
Length 126 Pages
SKU # PLRS20451511

Description

The U.S. artificial intelligence (AI) in manufacturing market size is expected to reach USD 89.98 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Artificial Intelligence in Manufacturing Market Size, Share, Trends, Industry Analysis Report By Component (Hardware, Software), By Technology, By Application, By End Use – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

AI in manufacturing refers to the use of artificial intelligence technologies such as machine learning platform, computer vision, and robotics to optimize production processes, improve quality control, and reduce downtime. It enables predictive maintenance, real-time monitoring, and automated decision-making across supply chains and factory operations.

Rising labor costs and a shortage of skilled workers in the U.S. manufacturing sector are prompting companies to invest in AI-driven automation. AI helps fill critical labor gaps by taking over repetitive or dangerous tasks, improving workplace safety and productivity. At the same time, AI-powered systems improve the effectiveness of existing workers by providing real-time data and decision support. This shift is particularly important in regions with aging workforces or where talent is hard to find. AI offers a practical and scalable solution to maintain output without compromising quality or safety as labor challenges persist, thereby driving the growth.

The U.S. manufacturers are prioritizing supply chain resilience and reshoring efforts following disruptions caused by the COVID-19 pandemic and geopolitical tensions. AI plays a critical role in this shift by improving supply chain visibility, predicting demand fluctuations, and optimizing logistics. Manufacturers are using AI to monitor real-time inventory, automate procurement decisions, and adapt quickly to external shocks. These capabilities are essential for creating agile, responsive supply chains that support local production. The national focus on economic resilience, combined with the need for just-in-time efficiency, makes AI a strategic tool in rebuilding and strengthening U.S.-based manufacturing operations, thereby fueling the adoption of AI in manufacturing.

U.S. Artificial Intelligence in Manufacturing Market Report Highlights

The hardware segment led the U.S. market in 2024, driven by increasing demand for high-performance computing systems, AI-enabled sensors, and robotics to enhance manufacturing efficiency and automation.

The computer vision segment witness notable growth in 2024, propelled by the rising need for intelligent visual inspection, real-time safety monitoring, and image-based analytics in key industries such as automotive, aerospace, and food manufacturing.

The production planning segment is expected to grow significantly as manufacturers prioritize agility and operational efficiency in response to changing consumer preferences, labor constraints, and persistent supply chain disruptions.

The medical devices segment accounted for the largest market share in 2024. The dominance is supported by the country’s advanced healthcare sector, strong innovation ecosystem, and strict regulatory requirements that emphasize precision, reliability, and compliance in manufacturing.

A few key players in the U.S. AI in manufacturing market are Microsoft Corporation; Mitsubishi Electric Corporation; NVIDIA Corporation; Oracle Corporation; Rethink Robotics; Rockwell Automation Inc; SAP SE; Siemens AG; Sight Machine; and Spark Cognition Inc.

Polaris Market Research has segmented the U.S. artificial intelligence in manufacturing market report based on component, technology, application, and end use:

By Component (Revenue - USD Billion, 2020–2034)

Hardware

Software

Services

By Technology (Revenue - USD Billion, 2020–2034)

Machine Learning (ML)

Computer Vision

Context Awareness

Natural Language Processing

By Application (Revenue - USD Billion, 2020–2034)

Material Movement

Predictive Maintenance & Machinery Inspection

Production Planning

Field Services

Quality Control & Reclamation

Others

By End Use (Revenue - USD Billion, 2020–2034)

Semiconductor & Electronics

Energy & Power

Medical devices

Automobile

Heavy Metal & Machine Manufacturing

Others

Table of Contents

126 Pages
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Europe Subcutaneous Immunoglobulin Market Insights
4.1. Europe Subcutaneous Immunoglobulin Market – Market Snapshot
4.2. Europe Subcutaneous Immunoglobulin Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Aging Population and Rising Chronic Disease Burden
4.2.1.2. Innovation in SCIG Formulations and Drug Delivery Technologies
4.2.2. Restraints and Challenges
4.2.2.1. Limited plasma supply and sourcing challenges
4.2.3. Public opinion and privacy legal precedents
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Europe Subcutaneous Immunoglobulin Market Trends
4.6. Value Chain Analysis
5. Europe Subcutaneous Immunoglobulin Market, By Product Type
5.1. Key Findings
5.2. Introduction
5.2.1. Europe Subcutaneous Immunoglobulin Market, By Product Type, by Country, 2020–2034 (USD Billion)
5.3. IgG
5.3.1. Europe Subcutaneous Immunoglobulin Market, by IgG, by Country, 2020–2034 (USD Billion)
5.4. IgA
5.4.1. Europe Subcutaneous Immunoglobulin Market, by IgA, by Country, 2020–2034 (USD Billion)
5.5. IgM
5.5.1. Europe Subcutaneous Immunoglobulin Market, by IgM, by Country, 2020–2034 (USD Billion)
6. Europe Subcutaneous Immunoglobulin Market, By Application
6.1. Key Findings
6.2. Introduction
6.2.1. Europe Subcutaneous Immunoglobulin Market, By Application, by Country, 2020–2034 (USD Billion)
6.3. Primary Immunodeficiency Disease
6.3.1. Europe Subcutaneous Immunoglobulin Market, by Primary Immunodeficiency Disease, by Country, 2020–2034 (USD Billion)
6.4. Secondary Immunodeficiency Disease
6.4.1. Europe Subcutaneous Immunoglobulin Market, by Secondary Immunodeficiency Disease, by Country, 2020–2034 (USD Billion)
7. Europe Subcutaneous Immunoglobulin Market, By End Use
7.1. Key Findings
7.2. Introduction
7.2.1. Europe Subcutaneous Immunoglobulin Market, By End Use, by Country, 2020–2034 (USD Billion)
7.3. Hospitals
7.3.1. Europe Subcutaneous Immunoglobulin Market, by Hospitals, by Country, 2020–2034 (USD Billion)
7.4. Homecare
7.4.1. Europe Subcutaneous Immunoglobulin Market, by Homecare, by Country, 2020–2034 (USD Billion)
7.5. Clinics
7.5.1. Europe Subcutaneous Immunoglobulin Market, by Clinics, by Country, 2020–2034 (USD Billion)
7.6. Others
7.6.1. Europe Subcutaneous Immunoglobulin Market, by Others, by Country, 2020–2034 (USD Billion)
8. Europe Subcutaneous Immunoglobulin Market, by Geography
8.1. Key Findings
8.2. Introduction
8.2.1. Europe Subcutaneous Immunoglobulin Market Assessment, By Geography, by Country, 2020-2034 (USD Billion)
8.3. Europe Subcutaneous Immunoglobulin Market – Europe
8.3.1. Europe: Subcutaneous Immunoglobulin Market, by Product Type, by Country, 2020-2034 (USD Billion)
8.3.2. Europe: Subcutaneous Immunoglobulin Market, by Application, by Country, 2020-2034 (USD Billion)
8.3.3. Europe: Subcutaneous Immunoglobulin Market, by End Use, by Country, 2020-2034 (USD Billion)
8.3.4. Europe Subcutaneous Immunoglobulin Market – UK
8.3.4.1. UK: Europe Subcutaneous Immunoglobulin Market, by Product Type, by Country, 2020-2034 (USD Billion)
8.3.4.2. UK: Europe Subcutaneous Immunoglobulin Market, by Application, by Country, 2020-2034 (USD Billion)
8.3.4.3. UK: Europe Subcutaneous Immunoglobulin Market, by End Use, by Country, 2020-2034 (USD Billion)
8.3.5. Europe Subcutaneous Immunoglobulin Market – France
8.3.5.1. France: Europe Subcutaneous Immunoglobulin Market, by Product Type, by Country, 2020-2034 (USD Billion)
8.3.5.2. France: Europe Subcutaneous Immunoglobulin Market, by Application, by Country, 2020-2034 (USD Billion)
8.3.5.3. France: Europe Subcutaneous Immunoglobulin Market, by End Use, by Country, 2020-2034 (USD Billion)
8.3.6. Europe Subcutaneous Immunoglobulin Market – Germany
8.3.6.1. Germany: Europe Subcutaneous Immunoglobulin Market, by Product Type, by Country, 2020-2034 (USD Billion)
8.3.6.2. Germany: Europe Subcutaneous Immunoglobulin Market, by Application, by Country, 2020-2034 (USD Billion)
8.3.6.3. Germany: Europe Subcutaneous Immunoglobulin Market, by End Use, by Country, 2020-2034 (USD Billion)
8.3.7. Europe Subcutaneous Immunoglobulin Market – Italy
8.3.7.1. Italy: Europe Subcutaneous Immunoglobulin Market, by Product Type, by Country, 2020-2034 (USD Billion)
8.3.7.2. Italy: Europe Subcutaneous Immunoglobulin Market, by Application, by Country, 2020-2034 (USD Billion)
8.3.7.3. Italy: Europe Subcutaneous Immunoglobulin Market, by End Use, by Country, 2020-2034 (USD Billion)
8.3.8. Europe Subcutaneous Immunoglobulin Market – Spain
8.3.8.1. Spain: Europe Subcutaneous Immunoglobulin Market, by Product Type, by Country, 2020-2034 (USD Billion)
8.3.8.2. Spain: Europe Subcutaneous Immunoglobulin Market, by Application, by Country, 2020-2034 (USD Billion)
8.3.8.3. Spain: Europe Subcutaneous Immunoglobulin Market, by End Use, by Country, 2020-2034 (USD Billion)
8.3.9. Europe Subcutaneous Immunoglobulin Market – Netherlands
8.3.9.1. Netherlands: Europe Subcutaneous Immunoglobulin Market, by Product Type, by Country, 2020-2034 (USD Billion)
8.3.9.2. Netherlands: Europe Subcutaneous Immunoglobulin Market, by Application, by Country, 2020-2034 (USD Billion)
8.3.9.3. Netherlands: Europe Subcutaneous Immunoglobulin Market, by End Use, by Country, 2020-2034 (USD Billion)
8.3.10. Europe Subcutaneous Immunoglobulin Market – Russia
8.3.10.1. Russia: Europe Subcutaneous Immunoglobulin Market, by Product Type, by Country, 2020-2034 (USD Billion)
8.3.10.2. Russia: Europe Subcutaneous Immunoglobulin Market, by Application, by Country, 2020-2034 (USD Billion)
8.3.10.3. Russia: Europe Subcutaneous Immunoglobulin Market, by End Use, by Country, 2020-2034 (USD Billion)
8.3.11. Europe Subcutaneous Immunoglobulin Market – Rest of Europe
8.3.11.1. Rest of Europe: Subcutaneous Immunoglobulin Market, by Product Type, by Country, 2020-2034 (USD Billion)
8.3.11.2. Rest of Europe: Subcutaneous Immunoglobulin Market, by Application, by Country, 2020-2034 (USD Billion)
8.3.11.3. Rest of Europe: Subcutaneous Immunoglobulin Market, by End Use, by Country, 2020-2034 (USD Billion)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. ADMA Biologics, Inc.
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Baxter International Inc.
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Biotest AG
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. CSL Behring
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. Grifols S.A.
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. Johnson & Johnson (Omrix Biopharmaceuticals Inc.)
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Kedrion S.p.A
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Octapharma AG
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. Pfizer Inc.
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development
10.10. Shanghai RAAS Blood Products Co. Ltd.
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Benchmarking
10.10.4. Recent Development
10.11. Takeda Pharmaceutical Company Limited
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Benchmarking
10.11.4. Recent Development
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.